Elsevier Science, Inc.

SHERPA: Unknown

People

  1. Horwitz
    Horwitz
  2. Zelenetz
    Zelenetz
  3. Palomba
    Palomba
  4. Noy
    Noy
  5. Moskowitz
    Moskowitz
  6. Abdel-Wahab
    Abdel-Wahab
  7. Dogan
    Dogan
  8. Kumar
    Kumar
  9. Roeker
    Roeker
  10. Schoder
    Schoder

Groups

  1. Center for Hematologic Malignancies (34)
  2. Department of Medicine (34)
  3. Hematologic Malignancies, Division of (34)
  4. Lymphoma (34)
  5. Executive Committee, Center for Hematologic Malignancies (11)
  6. Population Sciences Research Program (7)
  7. Survivorship Research (5)
  8. Biostatistics Service (4)
  9. Epidemiology and Biostatistics (4)
  10. GSK Faculty (4)
Search Within
  1. "Journal article"
  2. "Lymphoma"
Formats
  1. Journal Article (34)
Groups
  1. Center for Hematologic Malignancies (34)
  2. Department of Medicine (34)
  3. Hematologic Malignancies, Division of (34)
  4. Lymphoma (34)
  5. Executive Committee, Center for Hematologic Malignancies (11)
  6. Population Sciences Research Program (7)

More Groups

People
  1. Anas Younes (9)
  2. Andrew Zelenetz (7)
  3. Steven Horwitz (7)
  4. Maria Palomba (6)
  5. Ariela Noy (5)
  6. Matthew Matasar (5)

More People

Years
  1. 2023 (2)
  2. 2022 (3)
  3. 2021 (6)
  4. 2020 (4)
  5. 2019 (3)
  6. 2018 (4)

More Years

Publications
  1. Lancet Oncology (12)
  2. The Lancet Haematology (9)
  3. Lancet (4)
  4. Journal of Molecular Diagnostics (3)
  5. Academic Radiology (1)
  6. American Journal of Pathology (1)

More Publications

Results (34)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Brentuximab vedotin with AVD for stage II–IV HIV-related Hodgkin lymphoma (AMC 085): Phase 2 results from an open-label, single arm, multicentre phase 1/2 trial
    Journal Article

    Rubinstein, P. G.; Moore, P. C.; Bimali, M.; Lee, J. Y.; Rudek, M. A.; Chadburn, A.; Ratner, L.; Henry, D. H.; Cesarman, E.; DeMarco, C. E.; more...
    The Lancet Haematology (2023)

    Fulltext@MSK | Save
  • Validation of a high-sensitivity assay for detection of chimeric antigen receptor T-cell vectors using low-partition digital PCR technology
    Journal Article

    Arcila, M. E.; Patel, U.; Momeni-Boroujeni, A.; Yao, J.; Chan, R.; Chan, J.; Rijo, I.; Yu, W.; Chaves, N.; Patel, H.; more...
    Journal of Molecular Diagnostics (2023)

    Fulltext@MSK | Save
  • Predictors of major hemorrhage after spleen core biopsy in cancer patients
    Journal Article

    Kunin, H.; Wijetunga, N. A.; Erinjeri, J. P.; Noy, A.; Deipolyi, A. R.
    Journal of Vascular and Interventional Radiology (2022)

    Fulltext@MSK | Save
  • Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: A single-arm, multicentre, phase 2 study
    Journal Article

    Budde, L. E.; Sehn, L. H.; Matasar, M.; Schuster, S. J.; Assouline, S.; Giri, P.; Kuruvilla, J.; Canales, M.; Dietrich, S.; Fay, K.; more...
    Lancet Oncology (2022)

    Fulltext@MSK | Save
  • Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: A multicentre, first-in-patient, dose-escalation and dose-expansion, phase 1b trial
    Journal Article

    Pagel, J. M.; Soumerai, J. D.; Reddy, N.; Jagadeesh, D.; Stathis, A.; Asch, A.; Salman, H.; Kenkre, V. P.; Iasonos, A.; Llorin-Sangalang, J.; more...
    Lancet Oncology (2022)

    Fulltext@MSK | Save
  • Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: A multicentre, single-arm, phase 2 trial
    Journal Article

    Soumerai, J. D.; Mato, A. R.; Dogan, A.; Seshan, V. E.; Joffe, E.; Flaherty, K.; Carter, J.; Hochberg, E.; Barnes, J. A.; Hamilton, A. M.; more...
    The Lancet Haematology (2021)

    Fulltext@MSK | Save
  • Camidanlumab tesirine in patients with relapsed or refractory lymphoma: A phase 1, open-label, multicentre, dose-escalation, dose-expansion study
    Journal Article

    Hamadani, M.; Collins, G. P.; Caimi, P. F.; Samaniego, F.; Spira, A.; Davies, A.; Radford, J.; Menne, T.; Karnad, A.; Zain, J. M.; more...
    The Lancet Haematology (2021)

    Fulltext@MSK | Save
  • Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial
    Journal Article

    Straus, D. J.; Długosz-Danecka, M.; Connors, J. M.; Alekseev, S.; Illés, Á; Picardi, M.; Lech-Maranda, E.; Feldman, T.; Smolewski, P.; Savage, K. J.; more...
    The Lancet Haematology (2021)

    Fulltext@MSK | Save
  • Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): A double-blind, randomised, placebo-controlled, phase 3 trial
    Journal Article

    Matasar, M. J.; Capra, M.; Özcan, M.; Lv, F.; Li, W.; Yañez, E.; Sapunarova, K.; Lin, T.; Jin, J.; Jurczak, W.; more...
    Lancet Oncology (2021)

    Fulltext@MSK | Save
  • Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): A phase 1/2 study
    Journal Article

    Mato, A. R.; Shah, N. N.; Jurczak, W.; Cheah, C. Y.; Pagel, J. M.; Woyach, J. A.; Fakhri, B.; Eyre, T. A.; Lamanna, N.; Patel, M. R.; more...
    Lancet (2021)

    Fulltext@MSK | Save